LX2006
Gene Therapy Target: FXN, frataxin
- Friedreich Ataxia Cardiomyopathy
- Undisclosed indication
Lexeo Therapeutics, Inc.
Most recent annual filing: 2026-03-30
Pipeline (10 active programs)
LX2020
Gene Therapy Target: PKP2
- Arrhythmogenic Cardiomyopathy
- Undisclosed indication
LX2021
Gene Therapy Target: Cx43, connexin 43
LX2022
Gene Therapy Target: TNNI3, troponin I
LX1001
Gene Therapy Target: APOE4, APOE2
LX1021
Gene Therapy Target: APOE2, APOE4
LX1020
Gene Therapy Target: APOE2, APOE4
LX1004
Technology platforms
Sf9-baculovirus AAV manufacturing platform
Optimized Sf9 baculovirus suspension-based AAV manufacturing process offering improved scalability and reduced cost while maintaining purity and potency, supporting cardiac genetic medicine programs.
Biotech Distilled coverage (2)
- 2026-01-12 UPDATE: Lexeo (LXEO) Drops 25%+ on “Positive” Data – Why Did the Market Halt on the LX2020 Readout? 🔒 Paid
- 2025-12-22 Lexeo Therapeutics (LXEO): Scientific Due Diligence for Lead and Pipeline Products 🔒 Paid
Articles open on Substack. Some deep dives are subscriber-only.